Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2019

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPAL-BROADEN
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jun 2019 Pooled analysis results from OPAL Broaden and OPAL Beyond presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2019 Results (n=354) of post-hoc analysis of two phase 3 studies (OPAL Broaden and OPAL Beyond) assessing tofacitinib treatment in improvement of pain in psoriatic arthritis patients, presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2019 Results assessing additional dermatologic endpoints from OPAL Broaden and OPAL Beyond trials presented at the 20th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top